Zhejiang Starry Pharm Co Ltd (603520) — Capital Reinvestment Ratio
Zhejiang Starry Pharm Co Ltd (603520) has a Capital Reinvestment Ratio of 2.67x as of September 2025, meaning it reinvests 3% of its operating cash flow (CN¥9.76 Million) in capital expenditures (CN¥26.10 Million). See Zhejiang Starry Pharm Co Ltd (603520) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhejiang Starry Pharm Co Ltd Capital Reinvestment Ratio (2012–2025)
This chart tracks Zhejiang Starry Pharm Co Ltd's Capital Reinvestment Ratio across 13 annual periods.
Annual Capital Reinvestment Ratio for Zhejiang Starry Pharm Co Ltd (2012–2025)
Year-by-year Capital Reinvestment Ratio for Zhejiang Starry Pharm Co Ltd from 2012 to 2025. For live market cap and broader valuation context, see Zhejiang Starry Pharm Co Ltd (603520) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 73.42x | CN¥3.67 Million | CN¥269.20 Million | ▲ +2855.8% |
| 2024 | 2.48x | CN¥193.50 Million | CN¥480.62 Million | ▼ -57.0% |
| 2023 | 5.77x | CN¥46.13 Million | CN¥266.22 Million | ▲ +866.5% |
| 2021 | 0.60x | CN¥508.84 Million | CN¥303.88 Million | ▼ -32.0% |
| 2020 | 0.88x | CN¥174.48 Million | CN¥153.17 Million | ▲ +62.5% |
| 2019 | 0.54x | CN¥246.77 Million | CN¥133.28 Million | ▼ -36.2% |
| 2018 | 0.85x | CN¥191.84 Million | CN¥162.40 Million | ▼ -83.1% |
| 2017 | 5.01x | CN¥18.10 Million | CN¥90.62 Million | ▼ -79.6% |
| 2016 | 24.55x | CN¥7.68 Million | CN¥188.51 Million | ▲ +851.9% |
| 2015 | 2.58x | CN¥94.88 Million | CN¥244.66 Million | ▲ +79.6% |
| 2014 | 1.44x | CN¥144.00 Million | CN¥206.76 Million | ▼ -42.9% |
| 2013 | 2.51x | CN¥74.99 Million | CN¥188.42 Million | ▲ +87.8% |
| 2012 | 1.34x | CN¥103.34 Million | CN¥138.28 Million | — |